Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Guardant360 CDx
Other

Guardant360 CDx

Tracked across 1 events · 7 articles · First seen Jun 11, 2026 · Last active Jun 11, 2026

Sentiment
75
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 75
Regulatory
FDA approves Guardant360 CDx for HERNEXEOS
The United States — Food and Drug Administration (FDA) has approved Guardant360 CDx, a liquid biopsy test developed by Guardant Health, as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS (zongertinib tablets). HERNEXEOS is the first…
Impact: Guardant360 CDx received FDA approval as a companion diagnostic for HERNEXEOS, expanding its indications and reinforcing its role in personalized lung cancer care. This approval is the 27th CDx indication for the test.
Jun 11, 2026 · 7 articles
Key Actions (1)
100 United States — Food and Drug Administration approved Guardant360 CDxFDA approves Guardant360...
NEWSDESK
Track Guardant360 CDx live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.